For the Inventor, By the Inventor

Enter assignee name

La Jolla, CA, United States of America

Avidity Biosciences, Inc.

USPTO Granted Patents = 51

EPO Patents = 6

Trademarks = 14

Forward Citations = 387

Loading Chart...

Loading Chart...

30 inventors (with patents filed for the assignee):

Rob Burke (39 out of 42 patents)

Venkata Ramana Doppalapudi (35 out of 42 patents)

Beatrice Diana Darimont (35 out of 35 patents)

4. Michael Caramian Cochran (33 out of 35 patents)

5. Andrew John Geall (25 out of 100 patents)

6. Barbora Malecova (25 out of 25 patents)

7. David Sai-Ho Chu (21 out of 21 patents)

8. Yunyu Shi (14 out of 14 patents)

9. Gulin Erdogan Marelius (13 out of 18 patents)

10. Michael David Hood (13 out of 13 patents)

11. David Sala Cano (10 out of 10 patents)

12. Rachel Elizabeth Johns (9 out of 9 patents)

13. Hanhua Huang (8 out of 8 patents)

14. Palani Balu (6 out of 14 patents)

15. Arthur A Levin (5 out of 5 patents)

Core Competencies:

Muscle Dystrophy

Cardiomyopathy

Nucleic Acid-Polypeptide Compositions

Exon Skipping

Anti-Transferrin Receptor Antibodies

Facioscapulohumeral Muscular Dystrophy

Muscle Atrophy

Myotonic Dystrophy

PLN-Targeting Antibodies

Una Amidites

EGFR Nucleic Acids

KRAS Nucleic Acids

51 patents: Sort by Forward Citations

1. 12529056 - COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (2026-01-20),

2. 12497615 - NUCLEIC ACID COMPOSITIONS AND METHODS OF MULTI-EXON SKIPPING (2025-12-16),

3. 12491257 - COMPOSITIONS AND METHODS OF USING PRKAG2-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES (2025-12-09),

4. 12486328 - COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (2025-12-02),

5. 12427202 - Compositions and methods of treating muscle dystrophy (2025-09-30),

6. 12409230 - Compositions comprising PLN-targeting anti-transferrin receptor antibody-polynucleotides and methods of use thereof to treat cardiomyopathy (2025-09-09),

7. 12365704 - Nucleic acid-polypeptide compositions and uses thereof (2025-07-22),

8. 12364769 - Nucleic acid-polypeptide compositions and uses thereof (2025-07-22),

9. 12359202 - Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping (2025-07-15),

10. 12351637 - Nucleic acid-polypeptide compositions and uses thereof (2025-07-08),

11. 12263224 - Compositions and methods of treating muscle atrophy and myotonic dystrophy (2025-04-01),

12. 12234290 - Nucleic acid-polypeptide compositions and uses thereof (2025-02-25),

13. 12157774 - Compositions and methods of treating facioscapulohumeral muscular dystrophy (2024-12-03),

14. 12104156 - Compositions and methods of treating facioscapulohumeral muscular dystrophy (2024-10-01),

15. 12071621 - Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping (2024-08-27),

Avidity Biosciences is a biotechnology company focused on the development of targeted therapies for the treatment of rare muscle disorders. They are pioneering a proprietary technology platform called AOCs (Arcus™ Occurrence Catalytic System) that enables the targeted delivery of nucleic acids to muscle tissue. Avidity Biosciences is dedicated to advancing its pipeline of potential therapies to address the unmet needs of patients with rare muscle diseases.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 20 2026

51 Patents

#15 in La Jolla, CA

#1,583 in California

#6,660 in US

#13,404 in the World

La Jolla, CA, United States of America

Avidity Biosciences, Inc.

Forward Citations = 387

30 inventors:

Rob Burke (39 out of 42 patents)

Venkata Ramana Doppalapudi (35 out of 42 patents)

Beatrice Diana Darimont (35 out of 35 patents)

4. Michael Caramian Cochran (33 out of 35 patents)

5. Andrew John Geall (25 out of 100 patents)

Please report any incorrect information to support@idiyas.com

Loading…